I dentifying Alzheimer disease (AD) before patients meet criteria for dementia may be critical to effectively evaluate whether potential disease-modifying agents can alter the neurodegenerative process and long-term course of this illness. Defining prodromal AD (PDAD) using biomarkers associated with amyloidopathy and clinical criteria for mild cognitive impairment (MCI) has been proposed 1,2 as a way of identifying incipient AD dementia. Advances in cerebrospinal fluid (CSF) and neuroimaging biomarkers offer increasing sensitivity in identifying AD before the onset of dementia. 3, 4 Enriching clinical trials with patients who have both the clinical phenotype and underlying biomarker signature of AD will help ensure diagnostic accuracy, minimize exposure of individuals without AD to investigational agents, and increase the chances of detecting efficacy signals. A recent study 5 in patients with dominantly inherited AD found that structural and biochemical changes associated with AD begin years before the onset of clinically evident symptoms, supporting the notion that early intervention with a disease-modifying agent will be required to optimally affect symptom emergence and disease progression. Nonetheless, it remains to be established if fulfilling criteria for PDAD predetermines eventual development of dementia or simply represents a risk factor. Avagacestat (BMS-708163) is an oral γ-secretase inhibitor designed for the selective inhibition of β-amyloid (Aβ) synthesis relative to processing of Notch substrates. Phase 1 studies 6, 7 demonstrated that avagacestat decreased Aβ40 and Aβ42 levels at dosages expected to be tolerated in patients. Given that Aβ abnormality is an early marker of AD pathology and seems to change substantially throughout the course of MCI, 8, 9 avagacestat was advanced into a phase 2 PDAD clinical trial. [10] [11] [12] [13] [14] [15] We present the methods and results from this prospective, double-blind, placebo-controlled, randomized clinical trial designed to enrich for a study population at increased risk of progressing to dementia. In addition, we present data on patients meeting the clinical criteria for MCI but who were biomarker-negative in an observational cohort to assess the predictive value of using PDAD criteria to select patients at risk of progressing to dementia during the trial.
Methods
The treatment period of this multicenter, global, randomized, double-blind, 2-arm, placebo-controlled, parallelgroup, randomized clinical trial was planned to extend until at least 2 years after the last patient was randomized. Individuals who met clinical criteria for MCI, but not for PDAD (because of the absence of CSF biomarker evidence of AD pathology) were eligible to be monitored longitudinally in an observational cohort. Written informed consent was obtained from outpatients aged 45 to 90 years with MCI. The study was approved by an institutional review board designated by each site and was conducted in accordance with ethical principles and applicable regulatory requirements.
16, 17 The full study protocol can be found in Supplement 1. An independent datamonitoring committee had access to all study data and monitored the safety of participants on a quarterly basis throughout the trial. Patients at US sites and where allowed by local country regulations outside the United States received financial compensation for study visits and travel. (2) reveal no focal asymmetric lobar atrophy or other findings suggesting that the primary cause of dementia was better attributed to a cause other than AD, (3) reveal no more than mild to moderate white matter disease (1-2 lacunar infarcts were acceptable, but no lacunes were permitted in the anterior thalamus, genu of internal capsule, or basal forebrain; no cortical infarcts), (4) reveal no more than 4 cerebral microhemorrhages, and (5) reveal no current or prior evidence of macrohemorrhages (>10 mm). Exclusion criteria were as follows: (1) presence of a condition other than AD to explain the patient's cognitive symptoms, (2) previous stroke, (3) positive fecal test for occult blood at screening, (4) chronic inflammatory bowel disease, (5) frequent diarrhea or loose stools,(6) vitamin B 12 or folate deficiency, (7) Geriatric Depression Scale 24 score of 6 or higher at screening (suggesting clinical depression), and (8) exposure to an investigational agent related to Aβ modulation within 12 months before screening. Patients who received stable doses of approved AD medications for at least 2 months prior to screening or who remained free of such medications throughout the trial were also excluded ( Figure 1 ). After being informed that their CSF biomarker results did not qualify for randomization to the treatment arms of the study, individuals who met all other inclusion criteria were invited to consent and to be followed up longitudinally in the observational cohort.
Inclusion and Exclusion Criteria

Safety Assessments
Safety and tolerability were evaluated by reports of adverse events (AEs) and clinically meaningful changes in electrocar- 
CSF Biomarker Assessments
Lumbar punctures were performed at screening and optionally for randomized patients at week 2, week 24, and the end of treatment. The CSF levels of total tau, phosphorylated tau, and Aβ1-42 were analyzed (Luminex xMap technique, INNO-BIA AlzBio3 kit; Innogenetics) at a central laboratory. Levels of Aβ40 and Aβ42 were measured using electrochemiluminescence detection technology in multiplex format (Meso Scale Discovery). Cerebrospinal fluid levels of Aβ1-42 and total tau used for inclusion criteria were prospectively analyzed as patients were screened each week. In assessing changes in CSF biomarkers over time, baseline and on-treatment CSF samples from each patient were analyzed in the same analytical run to avoid any batch-to-batch assay variation. Patient flow in the randomized treatment phase (avagacestat vs placebo) for cerebrospinal fluid (CSF) biomarker-positive participants and the observational cohort for CSF biomarker-negative participants. After all participants in the treatment phase had the opportunity to receive double-blind treatment for at least 1 year, the study was terminated early after an interim analysis suggested a lack of efficacy on key clinical outcome measures. MCI indicates mild cognitive impairment; MRI, magnetic resonance imaging; and PET, positron emission tomography.
sults were evaluated centrally (BioClinica). Whole-brain and ventricular atrophy rates were computed using tensor-based morphometry, [30] [31] [32] and hippocampal atrophy was calculated using hippocampus boundary shift integral. 33 
PET Amyloid Assessments
Imaging using florbetapir F 18 positron emission tomography (PET) was performed in a subset of patients at baseline, week 24, and week 104 at selected sites. The florbetapir F 18 PET methods were performed blinded to patient assignment and analyzed as described previously 34, 35 under the direction of a central laboratory (Molecular NeuroImaging). Neocortical amyloid burden was expressed visually as either positive (consistent with an AD pattern of amyloidopathy) or negative (not consistent with an AD pattern of amyloidopathy), and quantitatively as the mean standard uptake value ratio for specific brain regions (posterior cingulate, parietal, lateral temporal, and frontal). The ratio was calculated as the target region standard uptake value divided by the brain tissue reference region, with the cerebellar cortex used as the reference region.
Randomization and Interventions
Patients with PDAD were randomly assigned (1:1) across the 2 blinded treatment groups: placebo or avagacestat once daily ( Figure 1 ). Patients assigned to the avagacestat group initially received 50 mg/d for the first 2 weeks and then 125 mg/d. An amendment to the protocol reduced the dose to 50 mg/d and allowed for down-titration to 25 mg/d owing to high treatment discontinuation rates at 125 mg/d. Treatment allocation was stratified based on concomitant cholinesterase inhibitor use (yes/no), apolipoprotein E ε4 (APOE4) carrier status (carrier/ noncarrier), and consent for PET scanning. Patient safety visits occurred every 2 weeks during the first 8 weeks of treatment, with telephone assessments occurring on alternating weeks. Follow-up visits were every 4 weeks until week 24 and every 12 weeks thereafter. On study termination, patients were monitored for 12 weeks after the last interim analysis to assess AEs and laboratory findings. A follow-up dermatologic examination was performed 6 months after treatment with the study drug was discontinued.
Statistical Analysis
The sample size of 135 participants per randomization arm was chosen empirically and was estimated to be associated with a 98% probability of observing a specific AE if the true incidence was 3%. The incidence of AEs and SAEs was tabulated by treatment group and summarized descriptively. The incidence of potentially clinically relevant changes or events in laboratory test values was tabulated by status at baseline (normal vs abnormal). An intent-to-treat approach was taken for the analysis of time to progression to dementia, while all evaluable patients were included in the analyses related to outcome measures requiring baseline and at least 1 treatment assessment.
For each cognition assessment, the change from baseline was analyzed using a mixed-effects, repeated-measures model with a restricted maximum likelihood estimation. Time was treated as a categorical variable. An unstructured covariance matrix was used to represent the correlation of the repeatedmeasures within-patient errors. The adjusted mean change score from baseline and the 95% CI for the treatment difference between avagacestat and placebo were calculated for each visit. For CSF biomarkers, the geometric mean over baseline of Aβ42 was analyzed. The mean change from baseline of total tau, phosphorylated tau, and volumetric MRI (hippocampal, ventricular, and whole brain) were also analyzed. No adjustments were made for multiple comparisons. Nominal P values were provided for descriptive purposes.
The PET substudy assessed the correlation between standard uptake values (mean of 4 assessed regions) and CSF Aβ42 concentrations. In addition, concordance was determined between PET-determined assessment of pathologic amyloid burden (using qualitative scale) and pathologic CSF at baseline.
Results
Demographic variables across the study groups are summarized in Table 1 . A total of 1358 patients were enrolled. Of these, 787 individuals (58.0%) were excluded prior to CSF testing. Of 571 patients who met the clinical inclusion criteria and completed the lumbar puncture, 263 participants (46.1%) met the CSF biomarker criteria for study entry and were randomized (Figure 1 ). Median treatment duration was approximately 22 months with a maximum of 41 months over both arms. After all participants had the opportunity to receive study treatment for at least 1 year, an interim analysis revealed minimal reductions in CSF amyloid and no significant treatment differences in the avagacestat arm vs placebo. The sponsor, in consultation with the DMC and external experts in the field, terminated the trial given the lack of apparent efficacy and unfavorable risk-benefit profile evident from the interim analysis.
Safety and Tolerability
Avagacestat doses of 50 mg/d were well tolerated with low treatment discontinuation rates, whereas the 125-mg/d dose had greater rates of discontinuation than placebo owing to gastrointestinal tract and skin AEs. Following this observation, the protocol was amended so that the highest dose was 50 mg/d with the ability to allow for down-titration to 25 mg/d. Fortysix patients in the avagacestat group and 44 patients in the placebo group down-titrated to doses of 25 mg/d for tolerability reasons. Discontinuation rates were similar between groups (19.6% at a dose of 50 mg/d and 43% at a dose of 125 mg/d). Common AEs in avagacestat patients included diarrhea, nausea, vomiting, fatigue, weight loss, decreased appetite, dizziness, and nonmelanoma skin cancer (NMSC) ( Table 2 and eTable 1 in Supplement 2). Incident cerebral microbleeds were observed in both the avagacestat (3.0%) and placebo (1.5%) groups, but none were considered symptomatic. Vasogenic edema occurred in 3 participants in the avagacestat arm and 1 in the placebo arm (none was considered symptomatic). No
Treatment-Emergent AEs and Laboratory Findings
Participants who received avagacestat demonstrated greater weight loss than did those who received placebo (mild, 6.1% vs 1.5%; moderate, 4.5% vs 0% weight loss). No significant differences in vital signs were observed between the groups. Treatment-emergent glycosuria, defined by any single positive urine glucose test result, was observed in 58.0% of avagacestat-treated patients but was not associated with treatment discontinuation, serum glucose changes, or evidence of glomerular injury. No decreases in glomerular filtration rate, cystatin C level, or clinically meaningful changes in albumin to creatinine or protein to creatinine ratios were found (eTable 2 in Supplement 2). Laboratory test abnormalities occurring in the avagacestat group at greater than twice the frequency observed in the placebo group included uric acid levels less than the lower limit of normal (men: avagacestat, 20 
Success of Screening Algorithm: Progression to Dementia Rates
Patients in the randomized (biomarker-positive) cohort progressed to dementia at a higher rate than did the observational (biomarker-negative) cohort (Figure 2) . Time-toprogression analysis did not suggest long-term differences between the randomized groups (hazard ratio, 1.354; 95% CI, 0.825-2.222). In the randomized group, the overall rates of progression were 8.9% and 19.7% for placebo and avagacestat, respectively, after 1 year and 29.0% and 30.7% for placebo and avagacestat, respectively, after 2 years. Longitudinal decline in the randomized groups was greater than in the observational cohort, as were rates of progression (4.9% after 1 year and 6.5% after 2 years).
Clinical Outcome Measures
Clinical outcomes across treatment arms are summarized in Table 3 . There were no statistically significant differences compared with placebo among treatment groups with regard to the Alzheimer's Disease Cooperative Study Activities of Daily Living MCI version, Alzheimer's Disease Assessment Scalecognitive subscale, Mini-Mental State Examination, and Clinical Dementia Rating Sum of Boxes outcome measures. Differential effects in subgroups based on APOE4 carrier status or background cholinesterase inhibitor use were not apparent. There were no statistically significant treatment differences by geographic region.
CSF Biomarkers and Volumetric MRI
The CSF Aβ biomarker results provided modest evidence of target engagement at the avagacestat, 50-mg/d, dose (eTable 4 in Supplement 2). At weeks 24 and 104, lowering of CSF Aβ40 
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Targeting Prodromal Alzheimer Disease With Avagacestat by 10% to 15% was noted for all dose groups. A reduction of 5% to 9% was noted in CSF Aβ42, which was not significantly different from placebo levels. Higher atrophy rates were observed in the avagacestat arm vs the placebo arm for whole brain, ventricles, and hippocampus as measured by volumetric MRI. The differences were significant at weeks 24 and 56 and were not significant at week 104, probably owing to the lower number of observations (eTable 5 in Supplement 2). This finding was consistent with previously reported 36, 37 brain atrophy results with other amyloid-lowering treatments. The observational cohort (20 participants) demonstrated approximately half the change in volume across all 3 regions at week 104 (±12 weeks) compared with the randomized cohort.
PET Substudy
The concordance between qualitative amyloid-positive PET and pathologic CSF was 87.7% (κ = 0.68; 95% CI, 0.48-0.87) (eFigure in Supplement 2). We found a statistically significant correlation between the mean standard uptake values across 4 areas of interest and the CSF total tau to Aβ42 ratio at baseline. Similar Spearman rank correlation coefficients were also observed with each of the 4 regions: posterior cingulate (0.41; P < .001), lateral temporal (0.53; P < .001), frontal lobe (0.52; P < .001), and parietal lobe (0.47, P < .001) (eTable 6 and eTable 7 in Supplement 2).
Discussion
The aims of this study were to assess the safety of avagacestat and demonstrate the feasibility of prospectively enriching a PDAD clinical trial population using biomarker criteria consistent with AD pathology. The study met its clinical trial enrichment aims but failed to demonstrate clinically meaningful pharmacodynamic effects of avagacestat.
Avagacestat treatment did not demonstrate signals of efficacy and was associated with dose-limiting effects on tolerability and safety. Doses of avagacestat, 50 mg/d, were well tolerated during long-term administration while doses of 125 mg/d were not tolerable and led to unacceptable rates of treatment discontinuation. Safety and tolerability of avagacestat, 50 mg/d, used for up to 46 months in the PDAD population were consistent with those observed in an earlier population with mild to moderate AD who received the drug for 6 months. 10 Although avagacestat was developed for its amyloid precursor protein selectivity over Notch, some of the AEs observed were likely related to Notch inhibition. In animal models, Notch inhibition is associated with goblet cell metaplasia 38 and
NMSCs. 39 In the present study, there were more cases of mild to severe colitis and NMSC among the avagacestat group than in the placebo arm. Similar trends were previously observed with avagacestat 10 and semagacestat. 40 The risk of incident NMSC appeared to abate 3 to 6 months after treatment discontinuation. Functional effects on proximal renal tubule cell function (as measured by asymptomatic laboratory changes in glycosuria, calcium, phosphate, and uric acid) were observed in this study, as described previously. 10 These effects included elevated rates of glycosuria accompanied by clinically nonsignificant decreases in serum uric acid, calcium, and potassium levels.
Although phase 1 studies 41 of avagacestat that were 1 month in duration suggested tolerable doses to achieve a mean 60% to 65% reduction in CSF amyloid levels, significant AEs were observed in the present phase 2 trial after longer-term use of the drug and necessitated dose reduction that was associated with only a modest effect on amyloid production. Avagacestat, 50 mg/d, minimally reduced (10%-15%) CSF Aβ40 levels. No diurnal variation was apparent, potentially attributable to the half-life of avagacestat being more than 48 hours. No significant differences were observed in key clinical outcome measures across treatment groups. The lack of a favorable clinical effect suggested a low likelihood that avagacestat would demonstrate meaningful clinical effects in longterm, large-scale studies. Progression to dementia was not significantly different between the avagacestat and placebo Number of study participants at risk at each time point who had not progressed to dementia. All participants met clinical criteria for mild cognitive impairment but only those in the randomized arms (avagacestat and placebo) met pathologic CSF biomarker criteria cutoff values of Aβ42 level of less than 200 pg/mL or total tau [T-tau]:Aβ42 ratio of 0.39 or greater. Observational cohort participants did not meet pathologic CSF criteria at study entry. Progression from prodromal AD to dementia was confirmed by an independent adjudication committee. At 2 years, rates of progression to dementia were 30.7% in avagacestat participants, 29.0% in the placebo group, and 6.5% in the observational cohort.
loid reduction would be adequate to achieve positive effects on clinical outcome measures.
Participants in the biomarker-positive group exhibited clinical decline, including progression to dementia that was greater than that observed in the biomarker-negative observational cohort, confirming the usefulness of PDAD criteria. Objective MRI measurements further support the clinical differentiation of the biomarker-positive vs biomarker-negative groups. The MRI volume change observed in the biomarkernegative cohort was approximately half that observed in the biomarker-positive group. Finally, we confirmed previous observations 42 that CSF amyloid levels correlated with PETamyloid imaging. This finding suggests that CSF and amyloid PET biomarkers may be used interchangeably to identify PDAD. The high screening failure rates among participants in our study suggests that efforts to refine entry criteria are needed to improve recruitment efficiency in clinical trials; however, changes to screening criteria must be carefully considered so as not to negatively affect the rates of cognitive decline or progression to dementia. Limitations of the present study include its small sample size, high screen failure rate in enrollment of participants, use of a research CSF amyloid assay not approved as a diagnostic test, and high intraindividual variability associated with the use of clinical rating scales. Additionally, investigators and study participants were aware of CSF biomarker results, which may have biased cognitive assessments in the biomarker-negative observational cohort. However, objective evidence, including MRI volumes (automated and semi-automated analytic procedures performed by blinded readers) as well as a review of all cases of clinical progression to dementia by an independent adjudication committee, support the observed differences in disease course between the biomarker-positive and -negative groups.
The enrichment strategy of enrolling individuals with PDAD who had a specific hippocampal pattern of memory impairment, an MRI pattern consistent with AD, and a supporting molecular diagnostic CSF biomarker pattern was successful in achieving the expected increased rates of dementia progression during the trial. However, not all participants with PDAD progressed to dementia during the study period. Longterm follow-up and additional prospective studies are needed to further validate the construct of PDAD vs simply describing such populations as "CSF-positive patients with MCI." Additional analyses of this study will add insights on the relative value of various baseline biomarkers (eg, patterns of atrophy on MRI, CSF biomarker profile, and PET radiotracer amyloid imaging) in predicting clinical progression.
Conclusions
This trial failed to demonstrate clinically meaningful effects of avagacestat on CSF amyloid biomarkers or clinical outcome measures. Although avagacestat was relatively well tolerated at 50 mg/d, minimal pharmacodynamic effects on amyloid reduction were observed at that dose. A higher incidence of AEs and untenable discontinuation rates at 125 mg/d precluded evaluation of avagacestat at doses associated with more robust reductions in CSF amyloid.
We believe this to be the first prospective randomized clinical trial in an amyloid biomarker-confirmed PDAD population. The findings provide important validation for the recently evolved nosology of prodromal stages of AD. The trial design was unique in that the biomarker criteria were predefined and each patient's CSF sample was analyzed in realtime prior to randomization. Although our study failed to demonstrate that avagacestat meaningfully affects the course of AD, the results show the feasibility of prospectively identifying PDAD and enriching a clinical trial population with patients at increased risk of progressing to dementia.
